GlassScriptPhysician profile
Jon Anthony Wagnon
NPI 1265623268
$2,284.89
in general payments reported to CMS, 2019-2025
24 companies · $283 in 2025
The $283 reported for 2025 was more than what 88% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $306 · 2021: $177 · 2022: $366 · 2023: $430 · 2024: $201 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.83 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $360.09 | 2019-2022 | |
| Lilly USA, LLC | $321.12 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $238.14 | 2021-2025 | Vraylar |
| Amgen INC. | $222.03 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $155.75 | 2019-2025 | Farxiga, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $132.54 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $129.43 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $106.56 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $104.95 | 2022-2025 | Livalo, Zoryve |
| Novo Nordisk INC | $65.78 | 2019-2023 | Wegovy, Saxenda |
| Janssen Pharmaceuticals, INC | $57.82 | 2019-2025 | Spravato |
| Insulet Corporation | $51.16 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $45.00 | 2019-2020 | |
| Allergan, INC. | $43.16 | 2020 | |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.47 | 2025 | Cologuard Collection Kit |
| Philips North America LLC | $31.86 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $31.33 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.40 | 2019 | |
| Pfizer INC. | $26.30 | 2022-2023 | |
| Janssen Biotech, INC. | $16.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.30 | 2022 | |
| Currax Pharmaceuticals LLC | $13.59 | 2023 | Contrave |
| Phadia US INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Wagnon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.